Plain-English translation of NCT06223542 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase I trial testing a new medication called TAK-243 in adults with advanced cancer that has not responded to standard treatments. The medication works by blocking a protein system in cancer cells that normally helps them survive. Researchers want to find the right dose and understand how safe and tolerable this treatment is.
Current treatments do not work for all advanced cancers, especially when tumors become resistant to standard therapy. This medication targets a new pathway in cancer cells, offering hope for patients who have run out of other treatment options.
You likely qualify if…
You likely don't qualify if…
You will receive the medication by IV infusion either twice per week (4 infusions every 3 weeks) or once per week (3 infusions every 4 weeks), depending on which group you are assigned to. You will have regular blood tests, imaging scans (CT or MRI), and may have small tumor biopsies and heart monitoring as needed. Study visits will happen frequently at first, then space out over time, and you will continue treatment as long as the cancer does not grow and side effects remain manageable.
AI-generated summary from trial data · Aug 17, 2026 · Not medical advice
United States